FIELD: pharmacology.
SUBSTANCE: group of inventions is an oral agent for oncological diseases treatment, comprising: a therapeutically effective amount of (S)-3-[(3-amino-1-pyrrolidinyl)carbonyl]-4,11-dihydroxy-2-methylanthra[2,3-b]furan-5,10-dione, represented by the formula: 
and a liquid pharmaceutically acceptable carrier comprising one or more solvents selected from water, polyethylene glycol, 1,2-polypropylene glycol, ethanol, glycerol. The oral agent may be a solid dispersion. The group of inventions includes a method for treatment of an oncological disease, comprising oral administration of a therapeutically effective amount of the described agent to a patient in need.
EFFECT: pharmaceuticals according to the invention provide high solubility of anthrafuran, rapid release of the active ingredient from pills or capsules, are stable during storage.
13 cl, 1 dwg, 8 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTITUMOUR ANTHRAFURANDIONE AND BASED PHARMACEUTICAL COMPOSITIONS | 2014 |
|
RU2554939C1 |
| ANTICANCER PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATING BREAST CANCER | 2015 |
|
RU2581022C1 |
| REMEDY POTENTIATING ANTI-TUMOUR EFFECT, AND ANTI-TUMOUR REMEDY | 2004 |
|
RU2334517C2 |
| IMPROVED THERAPEUTIC INDEX OF INHIBITORS AGAINST IMMUNE CHECKPOINT USING COMBINATION THERAPY INCLUDING PHY906 EXTRACT, SCUTELLARIA BAICALENSIS GEORGI (S) EXTRACT OR COMPOUND OF SUCH EXTRACTS | 2017 |
|
RU2753523C2 |
| COMBINED THERAPIES USING OF ANGIOGENESIS DAMAGING ACTIVITY | 2001 |
|
RU2268729C2 |
| COMBINATION OF A HISTONE DEACETYLASE INHIBITOR AND A PROTEIN KINASE INHIBITOR AND PHARMACEUTICAL APPLICATION THEREOF | 2019 |
|
RU2770754C1 |
| ANTITUMOR AGENT, ANTITUMOR ENHANCER AND ANTITUMOR KIT | 2017 |
|
RU2752172C2 |
| CAMPTOTHECIN DERIVATIVES, POSSESSING ANTITUMOUR ACTIVITY | 2012 |
|
RU2561118C2 |
| PHARMACEUTICAL COMPOSITIONS COMPRISING AROMATASE INHIBITOR | 2012 |
|
RU2617510C2 |
| COMPOSITION CONTAINING AN ALGAL PROTEOGLYCAN EXTRACT, AND USE THEREOF | 2017 |
|
RU2739558C2 |
